NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/02/2024
Voltar para busca
Dado oficial do USPTO
MEDIDELIC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
06/02/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
03/02/2021
Data de registro
06/02/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/02/2024
Última transação
06/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
28/11/2022
Primeiro uso no comércio
28/11/2022
Código do desenho
4
Tipo de titular
01
Localização do titular
Phoenix, AZ
Examinador
SULLIVAN,JOHN C
Unidade examinadora
M50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Newman, David
Representantes
Dean H. Kayes LAW OFFICE OF DEAN H. KAYES, P.C.
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Biotechnology research; Research and development in the pharmaceuticalbioenergetic imprinting and biotechnology fields; Providing information on the subject of scientific research in the field of biochemistrybiological signaling and biotechnology; Development of new technology for others in the field of biotechnology; Scientific Research and Development of AbsorptionDistributionMetabolismExcretion and Toxicity (ADMET) modelingphysiologically based pharmacokinetic (PBPK) and physiologically based biopharmaceutics (PBBM) modeling and simulation software for the pharmaceutical and biotechnology industries; Research and Development of software that allows pharmaceutical scientists to predict certain key potential endpoints and dynamicsin silicothereby reducing research and development costs and helping clients make better projects decisions sooner that includes PBBK (Physical based pharmacokinetics)PBBM (Physiologically based biopharmaceutics)NOAEL (No observed adverse effect level); Scientific Research and Development utilizing a proprietary algorithm and artificial intelligence that utilizes a combination of lifestylehospitalizationemergency room usemortality and outcomes data to assist the healthcare industry and workers in identifying groups at high risk and populations that can benefit from various therapeutic approaches; Scientific Research and Development of drugs and therapies through applying interactive maps that identify ideal target populations for various therapeutic approaches including the mapping of surfaces that apply socioeconomic and environmental factors such as access to or lack of access to transportation or nutritious foodexposure to high stress and artificial intelligence analysis considering the suitability of various drugs or therapies
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/01/2024
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/01/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
22/12/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
20/12/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
19/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
19/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
19/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
19/12/2023
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
19/12/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/09/2023
GNFR
FINAL REFUSAL E-MAILED
04/09/2023
CNFR
SU - FINAL REFUSAL - WRITTEN
04/09/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/08/2023
ALIE
ASSIGNED TO LIE
31/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/04/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
20/01/2023
GNRT
NON-FINAL ACTION E-MAILED
20/01/2023
CNRT
SU - NON-FINAL ACTION - WRITTEN
20/01/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
20/01/2023
IUAF
USE AMENDMENT FILED
10/01/2023
EISU
TEAS STATEMENT OF USE RECEIVED
10/01/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/12/2022
EX1G
SOU EXTENSION 1 GRANTED
30/11/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
29/11/2022
NREV
NOTICE OF REVIVAL - E-MAILED
24/10/2022
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
22/10/2022
PETG
PETITION TO REVIVE-GRANTED
22/10/2022
PROA
TEAS PETITION TO REVIVE RECEIVED
22/10/2022
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
06/09/2022
ABN6
ABANDONMENT - NO USE STATEMENT FILED
05/09/2022
EXT1
SOU EXTENSION 1 FILED
01/08/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/02/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/12/2021
PUBO
PUBLISHED FOR OPPOSITION
07/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/11/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/11/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/11/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/08/2021
GNRT
NON-FINAL ACTION E-MAILED
24/08/2021
CNRT
NON-FINAL ACTION WRITTEN
24/08/2021
DOCK
ASSIGNED TO EXAMINER
20/08/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/05/2021
NWAP
NEW APPLICATION ENTERED
06/02/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEDIDELIC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.